Cargando…
The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy
COPD is a leading cause of mortality and morbidity worldwide and is associated with a high socioeconomic burden. Current treatment includes the use of inhaled corticosteroids and bronchodilators, which can help to improve symptoms and reduce exacerbations; however, there is no solution for restoring...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217986/ https://www.ncbi.nlm.nih.gov/pubmed/37240045 http://dx.doi.org/10.3390/ijms24108702 |
_version_ | 1785048667615395840 |
---|---|
author | Riera-Martínez, Lluc Cànaves-Gómez, Laura Iglesias, Amanda Martin-Medina, Aina Cosío, Borja G. |
author_facet | Riera-Martínez, Lluc Cànaves-Gómez, Laura Iglesias, Amanda Martin-Medina, Aina Cosío, Borja G. |
author_sort | Riera-Martínez, Lluc |
collection | PubMed |
description | COPD is a leading cause of mortality and morbidity worldwide and is associated with a high socioeconomic burden. Current treatment includes the use of inhaled corticosteroids and bronchodilators, which can help to improve symptoms and reduce exacerbations; however, there is no solution for restoring lung function and the emphysema caused by loss of the alveolar tissue. Moreover, exacerbations accelerate progression and challenge even more the management of COPD. Mechanisms of inflammation in COPD have been investigated over the past years, thus opening new avenues to develop novel targeted-directed therapies. Special attention has been paid to IL-33 and its receptor ST2, as they have been found to mediate immune responses and alveolar damage, and their expression is upregulated in COPD patients, which correlates with disease progression. Here we summarize the current knowledge on the IL-33/ST2 pathway and its involvement in COPD, with a special focus on developed antibodies and the ongoing clinical trials using anti-IL-33 and anti-ST2 strategies in COPD patients. |
format | Online Article Text |
id | pubmed-10217986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102179862023-05-27 The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy Riera-Martínez, Lluc Cànaves-Gómez, Laura Iglesias, Amanda Martin-Medina, Aina Cosío, Borja G. Int J Mol Sci Review COPD is a leading cause of mortality and morbidity worldwide and is associated with a high socioeconomic burden. Current treatment includes the use of inhaled corticosteroids and bronchodilators, which can help to improve symptoms and reduce exacerbations; however, there is no solution for restoring lung function and the emphysema caused by loss of the alveolar tissue. Moreover, exacerbations accelerate progression and challenge even more the management of COPD. Mechanisms of inflammation in COPD have been investigated over the past years, thus opening new avenues to develop novel targeted-directed therapies. Special attention has been paid to IL-33 and its receptor ST2, as they have been found to mediate immune responses and alveolar damage, and their expression is upregulated in COPD patients, which correlates with disease progression. Here we summarize the current knowledge on the IL-33/ST2 pathway and its involvement in COPD, with a special focus on developed antibodies and the ongoing clinical trials using anti-IL-33 and anti-ST2 strategies in COPD patients. MDPI 2023-05-12 /pmc/articles/PMC10217986/ /pubmed/37240045 http://dx.doi.org/10.3390/ijms24108702 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Riera-Martínez, Lluc Cànaves-Gómez, Laura Iglesias, Amanda Martin-Medina, Aina Cosío, Borja G. The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy |
title | The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy |
title_full | The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy |
title_fullStr | The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy |
title_full_unstemmed | The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy |
title_short | The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy |
title_sort | role of il-33/st2 in copd and its future as an antibody therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217986/ https://www.ncbi.nlm.nih.gov/pubmed/37240045 http://dx.doi.org/10.3390/ijms24108702 |
work_keys_str_mv | AT rieramartinezlluc theroleofil33st2incopdanditsfutureasanantibodytherapy AT canavesgomezlaura theroleofil33st2incopdanditsfutureasanantibodytherapy AT iglesiasamanda theroleofil33st2incopdanditsfutureasanantibodytherapy AT martinmedinaaina theroleofil33st2incopdanditsfutureasanantibodytherapy AT cosioborjag theroleofil33st2incopdanditsfutureasanantibodytherapy AT rieramartinezlluc roleofil33st2incopdanditsfutureasanantibodytherapy AT canavesgomezlaura roleofil33st2incopdanditsfutureasanantibodytherapy AT iglesiasamanda roleofil33st2incopdanditsfutureasanantibodytherapy AT martinmedinaaina roleofil33st2incopdanditsfutureasanantibodytherapy AT cosioborjag roleofil33st2incopdanditsfutureasanantibodytherapy |